The US Food and Drug Administation (FDA) has approved Zokinvy to reduce risk of death due to Hutchinson-Gilford progeria syndrome and to treat some progeroid laminopathies.
The US Food and Drug Administration (FDA) has approved Zokinvy (lonafarnib) capsules from Eiger BioPharmaceuticals, Inc.1 The drug, which is a farnesyltransferase inhibitor, was approved to reduce the risk of death because of Hutchinson-Gilford progeria syndrome as well as treating certain processing-deficient progeroid laminopathies. It has been approved for use in children aged 1 year and older, but not approved for other progeroid syndromes or laminopathies.
The efficacy of Zokinvy was assessed in 62 patients who had been enrolled in 2 single-arm trials. In the studies, when compared to patients who were not treated, patients who had been administered Zokinvy had a lifespan that increased an average of 3 months during the first 3 years of treatment and, through the maximum follow-up period of 11 years, the average increase in lifespan was 2.5 years. Common side effects seen in the participants included nausea, vomiting, infection, diarrhea, fatigue, and decreased appetite.
The drug is contraindicated for co-administration with moderate of strong CYP3A inhibitors, certain cholesterol-lowering drugs, and midazolam. Additionally, some patients who were administered Zokinvy developed laboratory test abnormalities, like lowered white blood cell counts, increased liver blood tests, changes in blood sodium levels, and changes in blood potassium levels. Due to this possibility, it is recommended that routine blood laboratory testing occur on a periodic basis. Additionally, because of eye toxicity seen in animals, eye exams should be performed periodically or when visual changes are noted by patients.
In the press release for the drug’s approval, Hylton V. Joffe, MD, MMSc, director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA’s Center for Drug Evaluation and Research said “Hutchinson-Gilford progeria syndrome and progeroid laminopathies are rare genetic diseases that cause premature aging and death and have a debilitating effect on people’s lives. With today’s approval, Zokinvy is the first FDA-approved medication for these devastating diseases. The FDA will continue to work with stakeholders to advance the development of additional new, effective and safe therapies for these patients.”
Reference
1. US Food and Drug Administration. FDA approves first treatment for Hutchinson-Gilford progeria syndrome and some progeroid laminopathies. Published November 20, 2020. Accessed November 23, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.